Detail akcie Cassava Sci Rg online

Business Summary: Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Cassava Sciences Inc revenues was not reported. Net income totaled $25M vs. loss of $24.3M. Net income reflects Other Research & Develop decrease of 30% to $15.3M (expense), Other General & Admin decrease of 43% to $2.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.58 to $0.58.